Keyword Search
 
2017 | 2016 | 2015
Publication of UK Annual Report and Accounts & Notice of AGM
May 18, 2017
NEW YORK, May 18, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced its 2016 UK Annual Report and Accounts and notice of its Annual General Meeting have been posted to shareholders and will shortly be available for download from the Company’s website at www.motifbio.com. This follows the announcement made by the Company on May 2, 2017 via RNS of the publication of its fin... Read More
Motif Bio Appoints Scientific Opinion Leaders to Advisory Board
May 10, 2017
NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the appointment of Dr. Thomas Lodise, Dr. Thomas Holland and Dr. William O’Riordan to the Clinical Advisory Board. The three new advisory board members are medical and scientific leaders in their fields: Thomas Lodise, Pharm.D., Ph.D. is a Professor at Albany College of Pharmacy and Health Sciences, Al... Read More
Motif Bio Appoints Dr. Craig Albanese as Non-Executive Director
May 5, 2017
NEW YORK, May 05, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the appointment of Dr. Craig T. Albanese to the Company’s Board as Non-Executive Director with immediate effect. Dr. Albanese has 25 years of clinical and administrative experience focusing on children and women’s health, primarily in the Stanford Children’s Hospital, New-York Presbyterian Hospital, Mor... Read More
Motif Bio Reports Year-End 2016 Financial Results
May 1, 2017
NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. “Motif Bio made significant progress in 2016 towards our goal of bringing our novel antibiotic candidate, iclaprim, to patients with serious and life-threatening infections. The announcement of positive Phase 3 topline results for iclaprim in REVIV... Read More
Motif Bio Reports Year-End 2016 Financial Results
May 1, 2017
NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. "Motif Bio made significant progress in 2016 towards our goal of bringing our novel antibiotic candidate, iclaprim, to patients with serious and life-threatening infections. The announcement of positive Phase 3 topline results for iclaprim in REVIV... Read More
Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase 3 Study
April 18, 2017
Iclaprim met the primary endpoint   Iclaprim was well tolerated in the study   Data from the second Phase 3 ABSSSI Trial, REVIVE-2, expected in the second half of 2017   NDA submission expected in the first half of 2018 Company to host conference call today at 8:00 am EDT, 1:00 pm BST NEW YORK, April 18, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today ann... Read More
Motif Bio Phase 3 Clinical Trial Finishes Patient Treatment Phase
January 30, 2017
NEW YORK, Jan. 30, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced that the last patient has finished the treatment phase in REVIVE-1, the Phase 3 clinical trial investigating the safety and efficacy of iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).    REVIVE-1 is a 600-patient double-blinded, global, multicenter trial... Read More
Appointment of Chief Financial Officer
January 17, 2017
NEW YORK, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announces that Robert Dickey IV has been appointed as Chief Financial Officer. Mr. Dickey is an accomplished financial professional with senior leadership experience in private and public healthcare companies. Prior to joining Motif Bio, he was CFO at Tyme Technologies Inc., a NASDAQ-listed clinical stage on... Read More